Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 307Recurrence 64Neoplasms 32Neoplasms, Plasma Cell 17Lymphoma, Non-Hodgkin 14Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Vomiting 11Neoplasm Metastasis 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Nausea 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Ovarian Neoplasms 6Immunoglobulin Light-chain Amyloidosis 6Hematologic Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Paraproteinemias 5Lung Neoplasms 5Leukemia 5Small Cell Lung Carcinoma 4Renal Insufficiency 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Plasmacytoma 4Lymphoma, Follicular 4Hematologic Diseases 4Leukemia, Plasma Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3

Interventions

dacetuzumab 6Rituximab 6blinatumomab 4ibrutinib 3Ifosfamide 3Bortezomib 3ponatinib 2cobomarsen 2Vorinostat 2Lenalidomide 2Etoposide 2Dexamethasone 2Carboplatin 2tetulomab tetraxetan lu-177 1pegaspargase 1ficlatuzumab 1enzalutamide 1durvalumab 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vincristine 1Prednisone 1Methotrexate 1Lutetium 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Immunoproliferative Disorders × Dexamethasone × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡